The Neurology Center has made available three-month results of their randomized, double-blind, placebo controlled study of intravenously administering NuPlasma® young fresh frozen plasma into fourteen Multiple sclerosis disease patients.
HOUSTON, April 30, 2019 /PRNewswire/ -- The Neurology Center, a medical group practice of top doctors devoted to excellence in care, located in Houston, Texas, working in conjunction with two leading neurology and anti-aging specialists, has made available three-month results of their randomized, double-blind, placebo controlled study of intravenously administering NuPlasma® young fresh frozen plasma (yFFP®) into fourteen Multiple sclerosis (MS) disease patients (8 yFFP – 6 placebo).
MS is one of the world’s most common neurologic disorders and in many countries it is the leading cause of nontraumatic neurologic disability. Nearly one million people are living with MS in the United States.
MS is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. FDA-approved medications currently in use have been shown to “modify” the course of MS by reducing the number of relapses and delaying progression of disability to some degree, but do not constitute a cure.
The Neurology Center’s investigation into the efficacy of 25 ml/kg intravenous NuPlasma, administered in two doses over three days, realized sustained and statistically significant improvements:
- 39.1% reduction in the frequency of urination
- 28.9% reduction in weakness
- 26% improvement in sex life satisfaction
- 18.8% reduction in joint pain
- 17.1% reduction in headaches
- 10.7% improvement in energy
The initial one-month results, made available in February, were an encouraging indication of outcomes. After twelve weeks, this newly collected data takes the investigation past the point of where the yFFP is still in circulation. All patients continue to be maintained on their pre-investigation treatments. Critical disease improvements are believed to be directly attributable to the yFFP.
Full and continuing study disease assessment and blood laboratory data is accessible online at: www.youngplasmastudy.com.
About NuPlasma - NuPlasma is an accredited Blood Bank operating under FDA, AABB and CLIA’s Good Manufacturing Practice regulations. Located in San Marcos, Texas, NuPlasma is the world’s first blood bank to collect young plasma exclusively from volunteer 18 – 25 year old donors. NuPlasma is dedicated to Making Lives Better® by providing physicians with exceptional quality, selection and service.
*The use of blood and blood products such as plasma in the United States is restricted only to the issuance of a prescription by a licensed physician.
CONTACT: Young Plasma Study
PHONE: 512 749-4804
EMAIL: 213782@email4pr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/young-blood-plasma-multiple-sclerosis-study-three-month-results-show-sustained-improvements-in-critical-disease-conditions-such-as-frequency-of-urination-strength-sexual-satisfaction-joint-pain-headaches-and-energy-300840693.html
SOURCE The Neurology Center
